Traditional antidiabetic drugs do not always reduce the cardiovascular (CV) complications of diabetes; however, the potential applications of SGLT2 inhibitors in CV disease (Docherty et al., 2020; Heerspink et al., 2020; Slomski, 2020) have attracted increasing intense research interest. Here, SLC5A2 is linked to diabetes mellitus.